- Home
- CPIX vs SLGL Comparison
CPIX vs SLGL Comparison
Compare CPIX & SLGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CPIX
- SLGL
- Stock Information
- Founded
- CPIX 1999
- SLGL 1997
- Country
- CPIX United States
- SLGL Israel
- Employees
- CPIX N/A
- SLGL N/A
- Industry
- CPIX Biotechnology: Pharmaceutical Preparations
- SLGL Biotechnology: Pharmaceutical Preparations
- Sector
- CPIX Health Care
- SLGL Health Care
- Exchange
- CPIX Nasdaq
- SLGL Nasdaq
- Market Cap
- CPIX 40.1M
- SLGL 19.3M
- IPO Year
- CPIX 2009
- SLGL 2018
- Fundamental
- Price
- CPIX $3.65
- SLGL $8.54
- Analyst Decision
- CPIX
- SLGL Buy
- Analyst Count
- CPIX 0
- SLGL 1
- Target Price
- CPIX N/A
- SLGL $40.00
- AVG Volume (30 Days)
- CPIX 116.5K
- SLGL 25.5K
- Earning Date
- CPIX 08-05-2025
- SLGL 08-15-2025
- Dividend Yield
- CPIX N/A
- SLGL N/A
- EPS Growth
- CPIX N/A
- SLGL N/A
- EPS
- CPIX N/A
- SLGL N/A
- Revenue
- CPIX $41,083,299.00
- SLGL $12,103,000.00
- Revenue This Year
- CPIX N/A
- SLGL N/A
- Revenue Next Year
- CPIX N/A
- SLGL $31.17
- P/E Ratio
- CPIX N/A
- SLGL N/A
- Revenue Growth
- CPIX 5.82
- SLGL 603.66
- 52 Week Low
- CPIX $1.04
- SLGL $3.34
- 52 Week High
- CPIX $7.25
- SLGL $16.50
- Technical
- Relative Strength Index (RSI)
- CPIX 41.13
- SLGL 63.80
- Support Level
- CPIX $3.00
- SLGL $6.96
- Resistance Level
- CPIX $3.76
- SLGL $7.48
- Average True Range (ATR)
- CPIX 0.53
- SLGL 0.26
- MACD
- CPIX -0.02
- SLGL 0.07
- Stochastic Oscillator
- CPIX 27.95
- SLGL 100.00
About CPIX Cumberland Pharmaceuticals Inc.
Cumberland Pharmaceuticals Inc is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of branded prescription pharmaceutical products. The Company has one operating segment which is specialty pharmaceutical products. The company's target markets are hospital acute care, gastroenterology, rheumatology, and oncology. The company promotes its approved products through its hospital, field, and oncology sales divisions in the United States and establishes a network of international partners to register and provide medicines to patients in their countries. The company's revenue is derived from the product sales of FDA-approved pharmaceutical brands. Its brands include Acetadote, Caldolor, Kristalose, Omeclamox, Sancuso, Vaprisol and Vibativ.
About SLGL Sol-Gel Technologies Ltd.
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline includes SGT-610 (Patidegib Gel 2%), a new chemical entity hedgehog signaling pathway blocker, for the chronic use and prevention of new BCC in Gorlin syndrome patients, and the topical drug candidate SGT-210 for the treatment of Darier Disease and other rare keratosis-related indications such as PC, PPK and Olmsted.